Biotech Pharmaceuticals' broad-spectrum RAS inhibitor BPI-57.23 million enters the group as the first subject in Phase I clinical trial.

On January 29th, Beta Pharmaceuticals completed the enrollment of the first subject in the Phase I clinical trial of BPI-57.23 million capsules. BPI-572270, independently developed by Beta Pharmaceuticals, is an innovative drug that has not yet been approved for market in the world. It has a strong inhibitory effect on various tumor cells carrying different RAS mutations, has good pharmacokinetic characteristics, and has the best potential among similar drugs.